{"id":"cadonilimab-ak104","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":{"chemblId":"CHEMBL4594456","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By targeting both PD-L1 and TIM-3, cadonilimab overcomes dual immune checkpoint inhibition, allowing T cells to maintain activation and proliferation against cancer cells. This dual-checkpoint approach may provide superior efficacy compared to single-checkpoint inhibitors, particularly in tumors with high expression of both ligands.","oneSentence":"Cadonilimab is a bispecific antibody that simultaneously blocks PD-L1 and TIM-3 pathways to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:36.385Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Hepatocellular carcinoma"},{"name":"Other solid tumors (Phase 3 evaluation)"}]},"trialDetails":[{"nctId":"NCT05941741","phase":"PHASE3","title":"IC Plus Low-dose Radiation Plus Cadonilimab in LANPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-10","conditions":"Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy","enrollment":380},{"nctId":"NCT05824481","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-05-08","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":32},{"nctId":"NCT07446257","phase":"EARLY_PHASE1","title":"THIO and Cadonilimab in Resectable Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-05-01","conditions":"Resectable Hepatocellular Carcinoma","enrollment":60},{"nctId":"NCT07412613","phase":"PHASE3","title":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2026-03-15","conditions":"Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer","enrollment":386},{"nctId":"NCT05063916","phase":"PHASE2","title":"Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-28","conditions":"Carcinomas, Cervix Cancer, Cervical Cancer","enrollment":18},{"nctId":"NCT06789848","phase":"PHASE2","title":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-02-18","conditions":"Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Biliary Tract Cancer","enrollment":64},{"nctId":"NCT06851104","phase":"PHASE2","title":"A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence","status":"TERMINATED","sponsor":"Guangxi Medical University","startDate":"2025-02-16","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":45},{"nctId":"NCT05644379","phase":"PHASE1","title":"A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Advanced Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-11-24","conditions":"Advanced Hepatocellular Carcinoma That Has Failed at Least One Prior Systemic Therapy","enrollment":30},{"nctId":"NCT06654011","phase":"PHASE2","title":"IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-02-17","conditions":"Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma","enrollment":25},{"nctId":"NCT07263919","phase":"PHASE2","title":"Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-12-19","conditions":"Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma","enrollment":90},{"nctId":"NCT06448910","phase":"PHASE2","title":"Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fudan University","startDate":"2024-07-01","conditions":"NSCLC, Locally Advanced Lung Carcinoma","enrollment":41},{"nctId":"NCT06143748","phase":"PHASE2","title":"Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-03-02","conditions":"Esophagus Cancer","enrollment":46},{"nctId":"NCT05571644","phase":"PHASE2","title":"Neoadjuvant Treatment With mFOLFOXIRI Plus Cadonilimab (AK104) Versus mFOLFOX6 in Locally Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-07-10","conditions":"Colorectal Cancer","enrollment":143},{"nctId":"NCT06367075","phase":"PHASE2","title":"A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma","status":"RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2024-10-09","conditions":"Advanced Soft-tissue Sarcoma","enrollment":53},{"nctId":"NCT06494995","phase":"PHASE2","title":"AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-07-03","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT06998394","phase":"PHASE2","title":"A Single-Arm, Phase II Clinical Trail of Cadonilimab Combined With Chemoradiotherapy in Oligometastatic Stage IVB Cervical Cancer","status":"RECRUITING","sponsor":"Xiangbo Wan","startDate":"2025-03-12","conditions":"Cervical Cancer Stage IV","enrollment":30},{"nctId":"NCT06361758","phase":"PHASE2","title":"Second-line Treatment With CAdonilimab and LEnvatinib for Unresectable HCC","status":"WITHDRAWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-05-31","conditions":"Hepatocellular Carcinoma","enrollment":""},{"nctId":"NCT06762080","phase":"PHASE1, PHASE2","title":"Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis","status":"RECRUITING","sponsor":"Guangzhou Medical University","startDate":"2025-03-07","conditions":"Leptomeningeal Metastasis","enrollment":36},{"nctId":"NCT06946836","phase":"PHASE2","title":"Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2025-04-21","conditions":"Resectable Non-small Cell Lung Cancer, Bispecific Antibody, Neoadjuvant Therapy","enrollment":80},{"nctId":"NCT06913218","phase":"PHASE1","title":"A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC","status":"NOT_YET_RECRUITING","sponsor":"Akeso","startDate":"2025-07-22","conditions":"Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma","enrollment":60},{"nctId":"NCT05932212","phase":"PHASE2","title":"AK104 for Recurrent or Metastatic Vulvar Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-08-25","conditions":"Vulvar Cancer","enrollment":20},{"nctId":"NCT06617416","phase":"PHASE3","title":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-11-12","conditions":"NSCLC (Non-small Cell Lung Cancer)","enrollment":560},{"nctId":"NCT06560112","phase":"PHASE2","title":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-11-12","conditions":"Recurrent Ovarian Cancer","enrollment":172},{"nctId":"NCT05505825","phase":"PHASE1, PHASE2","title":"A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Akeso","startDate":"2022-08-26","conditions":"SCLC,Extensive Stage","enrollment":36},{"nctId":"NCT06371157","phase":"PHASE3","title":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-08-02","conditions":"Hepatocellular Carcinoma","enrollment":469},{"nctId":"NCT06832917","phase":"PHASE3","title":"Short-course Radiation (SCRT) Followed by 6 Cycles of Cadonilimab Plus MFOLFOX6 As Neoadjuvant Therapy for Patients with Locally Advanced Rectal Cancer (LARC): a Multicenter, Two-arm Parallel, Open-label, Randomised Phase III Trial (NeoCaCRT-III)","status":"NOT_YET_RECRUITING","sponsor":"Wan He","startDate":"2025-03-31","conditions":"Rectal Cancer","enrollment":238},{"nctId":"NCT05256472","phase":"PHASE2","title":"A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2023-07-06","conditions":"Renal Cell Carcinoma, First-line Treatment","enrollment":70},{"nctId":"NCT06511726","phase":"PHASE2","title":"Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2024-01-23","conditions":"Cervical Cancer","enrollment":29},{"nctId":"NCT06810895","phase":"","title":"Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix","status":"ENROLLING_BY_INVITATION","sponsor":"Ding Ma","startDate":"2025-02-01","conditions":"Cervix Cancer, Cadonilimab, Small Cell Neuroendocrine Carcinoma of the Cervix","enrollment":20},{"nctId":"NCT05792735","phase":"PHASE2","title":"Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Shenzhen People's Hospital","startDate":"2023-04-11","conditions":"Locally Advanced Rectal Carcinoma","enrollment":27},{"nctId":"NCT06405490","phase":"PHASE2","title":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-04-17","conditions":"Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin","enrollment":30},{"nctId":"NCT06035224","phase":"PHASE2","title":"A Study of Cadonilimab（AK104） Plus Lenvatinib in Previous Immunotherapy Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2023-08-23","conditions":"Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy","enrollment":28},{"nctId":"NCT06472037","phase":"PHASE2","title":"AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-07-01","conditions":"Locally Advanced Pancreatic Ductal Adenocarcinoma","enrollment":30},{"nctId":"NCT06401005","phase":"PHASE2","title":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","status":"RECRUITING","sponsor":"Hubei Cancer Hospital","startDate":"2024-11-28","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT06650332","phase":"PHASE1, PHASE2","title":"Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-07-10","conditions":"Metastatic HER2 Positive Gastroesophageal Junction Cancer","enrollment":90},{"nctId":"NCT06620796","phase":"PHASE2","title":"A Phase II Study of Ivonescimab Combined with Cadonilimab and Chemotherapy in Extensive-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","startDate":"2024-09-30","conditions":"SCLC, Extensive Stage","enrollment":70},{"nctId":"NCT05687851","phase":"PHASE2","title":"Study Of Cadonilimab Combined With Radiotherapy In The Treatment of Locally Advanced Cervical Cancer","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2022-12-29","conditions":"Locally Advanced Cervical Cancer","enrollment":33},{"nctId":"NCT06587425","phase":"PHASE2","title":"The Efficacy and Safety of LM-302 in Combination With Candonilimab and Capecitabine for First-Line Treatment in Patients With Unresectable Advanced, Recurrent, or Metastatic CLDN18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2024-07-31","conditions":"Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":50},{"nctId":"NCT06289751","phase":"PHASE2","title":"Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-09-03","conditions":"Cervical Cancer, Neoadjuvant Chemoimmunotherapy, Radical Hysterectomy","enrollment":50},{"nctId":"NCT06577961","phase":"PHASE1, PHASE2","title":"Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-31","conditions":"Kidney Cancer, RCC, Renal Cell Carcinoma","enrollment":37},{"nctId":"NCT06566755","phase":"PHASE3","title":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","status":"RECRUITING","sponsor":"Caigang Liu","startDate":"2024-02-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06532539","phase":"PHASE2","title":"Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-06-13","conditions":"Endometrial Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis","enrollment":30},{"nctId":"NCT06455254","phase":"PHASE2","title":"Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLM","status":"RECRUITING","sponsor":"Jin-hong Chen","startDate":"2024-07-11","conditions":"CRC","enrollment":44},{"nctId":"NCT06492317","phase":"PHASE2","title":"RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2024-07-06","conditions":"HER2-positive Gastric Cancer","enrollment":20},{"nctId":"NCT06477523","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC","status":"RECRUITING","sponsor":"Sichuan University","startDate":"2024-05-16","conditions":"SCLC, Extensive Stage","enrollment":57},{"nctId":"NCT06196697","phase":"PHASE2","title":"AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer","status":"RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-04-10","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":50},{"nctId":"NCT06341335","phase":"PHASE3","title":"A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2024-06-19","conditions":"Gastric and Gastroesophageal Junction Adenocarcinoma","enrollment":506},{"nctId":"NCT06467500","phase":"PHASE2","title":"A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy","status":"RECRUITING","sponsor":"Xin-Hua Xu","startDate":"2024-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT05816499","phase":"PHASE1, PHASE2","title":"Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Chest Hospital","startDate":"2023-02-16","conditions":"NSCLC Stage IV, NSCLC Stage IIIB, NSCLC Stage IIIC","enrollment":50},{"nctId":"NCT06455046","phase":"PHASE2","title":"Efficacy and Safety of AK104 Combined With Chemotherapy and Recombinant Human Adenovirus 5 Injection in Cervical Cancer","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-10-11","conditions":"Cervical Cancer Recurrent","enrollment":37},{"nctId":"NCT06427057","phase":"PHASE2","title":"A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-07-01","conditions":"Urinary System Tumor","enrollment":40},{"nctId":"NCT06424626","phase":"PHASE1","title":"A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2024-05-21","conditions":"Melanoma, Mucosal Melanoma, Metastatic Melanoma","enrollment":60},{"nctId":"NCT06416930","phase":"PHASE2","title":"Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-06-20","conditions":"Pleural Mesothelioma","enrollment":59},{"nctId":"NCT06406634","phase":"PHASE2","title":"Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-05-15","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT05817214","phase":"PHASE2","title":"Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer","status":"RECRUITING","sponsor":"Zhongnan Hospital","startDate":"2023-02-16","conditions":"Cervical Cancer","enrollment":35},{"nctId":"NCT05856864","phase":"PHASE1","title":"Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2024-06-01","conditions":"Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy","enrollment":30},{"nctId":"NCT06349967","phase":"PHASE2","title":"Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2024-04-30","conditions":"Gastric Cancer","enrollment":59},{"nctId":"NCT06221748","phase":"PHASE2, PHASE3","title":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","status":"RECRUITING","sponsor":"RemeGen Co., Ltd.","startDate":"2024-02-22","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":90},{"nctId":"NCT06215651","phase":"PHASE2","title":"Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-03-11","conditions":"Cadonilimab and Lenvatinib","enrollment":30},{"nctId":"NCT06327698","phase":"PHASE2","title":"Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure","status":"NOT_YET_RECRUITING","sponsor":"Hunan Cancer Hospital","startDate":"2024-05-15","conditions":"Melanoma","enrollment":30},{"nctId":"NCT06310473","phase":"PHASE2","title":"Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2024-03","conditions":"Gastric Cancer, Esophagogastric Junction Cancer","enrollment":30},{"nctId":"NCT05930665","phase":"PHASE2","title":"Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-01","conditions":"Pleural Mesothelioma","enrollment":38},{"nctId":"NCT05377658","phase":"PHASE2","title":"AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer","status":"RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2022-07-26","conditions":"Non-small Cell Lung Cancer","enrollment":43},{"nctId":"NCT06251388","phase":"PHASE2","title":"A Study of Concurrent Chemoradiotherapy Followed by Cadonilimab（AK104） for Newly Diagnosed Local Advanced Cervical Cancer","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2024-02-20","conditions":"Cervical Cancer","enrollment":50},{"nctId":"NCT05980689","phase":"PHASE2","title":"Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-10-24","conditions":"Locally Advanced Rectal Cancer","enrollment":33},{"nctId":"NCT06066216","phase":"PHASE2","title":"Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2024-02-01","conditions":"Endometrial Cancer, Endometrial Adenocarcinoma","enrollment":45},{"nctId":"NCT06202313","phase":"PHASE2","title":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2024-02-10","conditions":"Triple Negative Breast Cancer","enrollment":128},{"nctId":"NCT06196775","phase":"PHASE2","title":"A Study of Cadonilimab Combined With AK112 as Second-line Therapy in Patients With Advanced Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Harbin Medical University","startDate":"2024-01-31","conditions":"Hepatocellular Carcinoma","enrollment":36},{"nctId":"NCT06178601","phase":"PHASE2","title":"A Study of RC48-ADC Combined With Cadonilimab（AK104）in the Treatment of HER2-expression Locally Advanced or Metastatic Urothelial Carcinoma","status":"RECRUITING","sponsor":"Shanxi Province Cancer Hospital","startDate":"2023-08-03","conditions":"Urothelial Carcinoma","enrollment":36},{"nctId":"NCT06092645","phase":"PHASE2","title":"Surufatinib Plus Cadonilimab in Patients With Unresectable or Metastatic Bile Duct Adenocarcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2023-10-30","conditions":"Bile Duct Adenocarcinoma","enrollment":48},{"nctId":"NCT06074484","phase":"PHASE2","title":"A Study of RC48-ADC Combined With AK104 For Perioperative Treatment of Muscle-Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-09-10","conditions":"Muscle Invasive Bladder Carcinoma","enrollment":36},{"nctId":"NCT06062589","phase":"","title":"AK104 Combined With I-125 Brachytherapy for Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-10-11","conditions":"Cervical Cancer","enrollment":18},{"nctId":"NCT06040177","phase":"PHASE1, PHASE2","title":"Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2023-02-02","conditions":"Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus, Immune Checkpoint Inhibitors","enrollment":30},{"nctId":"NCT06023875","phase":"PHASE2","title":"Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Xuekui Liu","startDate":"2023-07-19","conditions":"Head and Neck Squamous Cell Carcinoma, Locally Advanced Operable","enrollment":30},{"nctId":"NCT06009848","phase":"PHASE2","title":"Cadonilimab Plus Nab-Paclitaxel for Recurrent or Metastatic Muscle Invasive Bladder Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Second Hospital","startDate":"2022-10-10","conditions":"Bladder Cancer","enrollment":20},{"nctId":"NCT06001151","phase":"PHASE2","title":"Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2023-08-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":49},{"nctId":"NCT05947201","phase":"PHASE2","title":"Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Weijia Fang, MD","startDate":"2023-05-08","conditions":"The Efficacy and Safety of Therapy Efficacy for Locally Advanced ESCC","enrollment":26},{"nctId":"NCT05948449","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Cadonilimab With SOX as Neoadjuvant Therapy for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.","status":"UNKNOWN","sponsor":"Sichuan University","startDate":"2023-07","conditions":"Gastric Cancer","enrollment":37},{"nctId":"NCT05901584","phase":"PHASE2","title":"Cadonilimab (AK104) With or Without CT as 2rd Line Treatment for ES-SCLC","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Zunyi Medical University","startDate":"2023-01-01","conditions":"Immunotherapy, Second-line Treatment","enrollment":30},{"nctId":"NCT05898256","phase":"PHASE1, PHASE2","title":"Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Guangxi Medical University","startDate":"2023-08-01","conditions":"Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors","enrollment":20},{"nctId":"NCT05833971","phase":"PHASE2","title":"Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2023-05-01","conditions":"Resectable Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy","enrollment":43},{"nctId":"NCT05790200","phase":"PHASE2","title":"Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2023-04-01","conditions":"Nasopharyngeal Carcinoma","enrollment":30},{"nctId":"NCT05732662","phase":"PHASE2","title":"SBRT Combined With AK104 to Treatment Relapsed or Metastatic ESCC","status":"NOT_YET_RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2023-04","conditions":"Recurrent or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":25},{"nctId":"NCT05656144","phase":"PHASE2","title":"Cadonilimab in the Treatment of Advanced Soft Tissue Sarcoma","status":"UNKNOWN","sponsor":"Peking University Cancer Hospital & Institute","startDate":"2023-02","conditions":"Soft Tissue Sarcoma","enrollment":49},{"nctId":"NCT05578430","phase":"PHASE2","title":"AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-01-01","conditions":"Resectable Hepatocellular Carcinoma","enrollment":54},{"nctId":"NCT05644392","phase":"PHASE1","title":"A Study Evaluating Cadonilimab Injection in Combination With Regorafenib for the Treatment of Biliary Systemic Tumours","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-11-25","conditions":"Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy","enrollment":30},{"nctId":"NCT05522894","phase":"PHASE2","title":"AK104 Alone or in Combination With Chemotherapy in the First-line Treatment of ESCC","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2022-10-01","conditions":"Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Concurrent Chemoradiotherapy"],"phase":"phase_3","status":"active","brandName":"Cadonilimab (AK104)","genericName":"Cadonilimab (AK104)","companyName":"Guangxi Medical University","companyId":"guangxi-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cadonilimab is a bispecific antibody that simultaneously blocks PD-L1 and TIM-3 pathways to enhance anti-tumor immune responses. Used for Non-small cell lung cancer, Hepatocellular carcinoma, Other solid tumors (Phase 3 evaluation).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}